In sum, our study not only emphasizes the promising potential of csGRP78 as a universal target for cancer therapy but also introduces a GRP78‐targeting immunotoxin as a potent agent against csGRP78‐expressing tumors. This evidence concerns the gene HSPA5 and cancer.